You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 1 - 10 of 4744 results
  1. A Novel Pharmacological Inhibitor of Adenylyl Cyclase Type 5 to Treat Alzheimer's Disease

    SBC: VASADE BIOSCIENCES, INC.            Topic: NIA

    Project Summary: Alzheimer’s Disease is associated with metabolic dysfunction, glucose and insulin resistance, oxidative stress, mitochondrial dysfunction, and reduced exercise capacity. Oxidative stress and mitochondrial dysfunction correlate with the development of beta-amyloid (Aβ) deposits, one of the hallmarks of AD that begin years before the onset of memory and cognitive decline. Moreove ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Next-generation nanomedicine for acute ischemic stroke

    SBC: Nanomuse, LLC            Topic: NINDS

    ABSTRACT / PROJECT SUMMARYAcute ischemic stroke is poised for a revolution. With the advent of mechanical thrombectomy in the last decade, the worst clots can be removed. While thrombectomy has improved outcomes, most treated patients still have severe deficits, in large part due to secondary injury caused by ischemia-reperfusion injury. To solve this problem, many neuroprotective drugs were trial ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Affordable, UV-, heat- and water-resistant radiochromic film composed of diacetylenes having chromophoric groups

    SBC: JP LABORATORIES INC            Topic: 300

    Project Summary: Self-developing, instant radiochromic films based on the solid-state polymerization of diacetylenes (R-C≡C-C≡C- R’, where R and R’ are substituent groups) are used for measuring radiation therapy dose. Currently available radiochromic films, e.g., the GafChromicTM EBT films from Ashland (Bridgewater, NJ, USA), have many drawbacks such as they are very expensive, sensitive ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Development of compound RUEC2-118, a novel partial GABAAR positive modulator, a fast-acting treatment for general anxiety and panic disorder, to prevent opioid and benzodiazepine overdose fatalities.

    SBC: Zena Therapeutics Inc.            Topic: NIDA

    Opioid use disorder (OUD) is highly prevalent among individuals with diagnosed anxiety disorders with more than 60% of individuals with OUD reporting a lifetime anxiety disorder. Co-occurring anxiety is linked to earlier and more rapid progression into OUD, poorer treatment outcomes, and high probability of co-use of other substances, particularly benzodiazepines (BZDs). BZDs are currently the sta ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a novel broad spectrum antifungal therapeutic targeting Glycosylphosphatidylinositol (GPI) biosynthesis and cell wall biogenesis

    SBC: Prokaryotics, Inc.            Topic: NIAID

    Widespread azole resistance among Candida and Aspergillus spp. along with emerging echinocandin resistance in C. glabrata and C. auris raises the specter of untreatable multidrug resistant fungal infections, even as advances in medicine (cancer chemotherapy, organ transplant, premature infants, HIV/AIDS therapy) have increased the size of the vulnerable population. Our proposal aims to develop a n ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Recombinant E-NTPDase for shock

    SBC: Purine Pharmaceuticals Inc.            Topic: 300

    SUMMARYInflammation after ischemia and reperfusion injury secondary to hemorrhagic shock is responsible for significant mortality and morbidity in the United States. Available intravenous fluids administered at the incident scene to treat hypovolemic shock do not completely prevent ischemia and reperfusion injury. Re-initiation of blood flow causes activation of several inflammatory mediators, suc ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Expansion and validation of novel mobile app for guiding home modifications for aging in place

    SBC: HomesRenewed Ventures LLC            Topic: R

    PROJECT SUMMARY In this Phase II SBIR, HomesRenewed Ventures, LLC (HRV Washington, DC) will build on our previous efforts to expand and validate an interactive mobile application (APP) for guiding home modifications (environmental interventions) critical to Aging in Place (AiP). Home modifications (HM) are associated with falls preventions, improved activities of daily living (ADLs), and emotional ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. A Redesigning Existing Drugs against Indispensable Targets (ReEDIT) platform technology for discovery of novel drugs to treat fungal infections

    SBC: KATHERA BIOSCIENCE INC.            Topic: NIAID

    Project Summary There is a worldwide need for improved treatment of systemic, life-threatening fungal infections. Current therapies are limited by the small number of approved drugs, toxicities, drug-drug interactions, mode of administration, and growing problems of drug resistance and emerging pathogens. Treatment also suffers from a lack of rapid clinical diagnoses, leading to dependence on broa ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. High-throughput functional analysis and clinical relevance of all possible variants of a gene

    SBC: HELIGENICS, INC.            Topic: NHGRI

    Modern pharmaceuticals have greatly improved the quality of life for many patients suffering a variety of illnesses. Unfortunately, among the 17 most commonly prescribed drugs, only 6 are highly effective for most patients, 5 have a modest effect, and 6 show little clinical effect. Worse still, unwanted illness and death from treatment of patients with the incorrect drug or dosage causes over 275, ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Novel hand hygiene product to remove Clostridioides difficile spores

    SBC: Novaflux Inc.            Topic: NIAID

    7. Project Summary/AbstractC. difficile now causes more hospital-onset infections and deaths in the US than any other pathogen and is the most important cause of healthcare-associated diarrhea among adults in industrialized countries. In 2017, there were an estimated 462,100 combined healthcare- and community-associated C. difficile infection cases in the US, and 20,500 in-hospital deaths. In a ra ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government